Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
By R. Bergenstal, C. Wysham, L. Macconell, Jaret Malloy, B. Walsh, P. Yan, Ken Wilhelm, J. Malone, L. Porter. The Lancet, 2010
620 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/488a0077c17a49887eed6cfd30d3fdba5a53355d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Update on the treatment of type 2 diabetes mellitus. (2016, background): “Exenatide LAR: Administration of exenatide LAR was proved more effective than highest dose of exenatide twice-daily [193,194] , sitagliptin and pioglitazone [195] , and insulin glargine [196] in T2DM patients treated with oral hypoglycaemic agents.”